Bevacizumab biosimilar (Bionovis/The Instituto Vital Brazil)

贝伐珠单抗生物类似药 (Bionovis/The Instituto Vital Brazil)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBevacizumab biosimilar (Bionovis/The Instituto Vital Brazil)

Drug Alias Name贝伐单抗生物仿制药 (Bionovis/The Instituto Vital Brazil)Bevacizumab biosimilar - Bionovis/The Instituto Vital Brazil贝伐赛珠单抗生物仿制药 (Bionovis/The Instituto Vital Brazil)贝伐珠单抗生物仿制药 (Bionovis/The Instituto Vital Brazil)贝伐人源化单抗生物仿制药 (Bionovis/The Instituto Vital Brazil)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsBreast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesBionovis The Instituto Vital Brazil

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBionovis The Instituto Vital Brazil

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsBreast Neoplasms +[4]

Other Information

ATC CodeL01XC07